Tonix Pharmaceuticals CEO talks through 2021 highlights, ending year with $179M in cash - Video

Tonix Pharmaceuticals Holding Corp. CEO Seth Lederman talks to Proactive about the New Jersey-based clinical-stage biopharmaceutical company's 2021 highlights. Lederman says the group ended the year with $179 million in cash and cash equivalents, entering 2022 'poised for growth.' Lederman highlights the FDA's recent award of Orphan-Drug designation for Tonix's TNX-2900 to treat Prader Willi syndrome, among other milestones.